Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.
The development of drug resistance by tumor cells is a major obstacle to the cure of human malignancy. Cyclosporin A (CsA) completely reverses primary resistance to vincristine and cross resistance to daunorubicin in a pleiotropic drug-resistant subline of human T cell acute lymphatic leukemia. This subline is over 50-fold resistant to vincristine and fivefold resistant to daunorubicin. CsA has little effect on vincristine or daunorubicin activity in drug-sensitive parental leukemia and corrects daunorubicin resistance without altering cellular daunorubicin accumulation.
Slater
L M
LM
Sweet
P
P
Stupecky
M
M
Gupta
S
S
D002460:Cell Line; D003524:Cyclosporins / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004351:Drug Resistance; D004357:Drug Synergism; D066298:In Vitro Techniques; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use*
D003524:Cyclosporins; D014750:Vincristine; D003630:Daunorubicin